Galvus
Galvus (vildagliptin) is an oral antihyperglycemic agent belonging to the dipeptidyl peptidase-4 (DPP-4) inhibitor class. It works by inhibiting the degradation of incretin hormones, thereby increasing insulin secretion and decreasing glucagon secretion in a glucose-dependent manner.
Dosage by Body Weight
The standard adult dose is 50 mg once or twice daily (maximum 100 mg per day). When used in dual therapy with a sulfonylurea, the recommended dose is 50 mg once daily. It can be taken with or without food. Dosage adjustments may be required for patients with moderate to severe renal impairment.
- Body Weight
- Below 5 kg
- Dose
- Not recommended
- Frequency
- Not applicable
- Tracking Notes
- Safety and effectiveness in pediatric patients have not been established.
- Body Weight
- 5-7 kg
- Dose
- Not recommended
- Frequency
- Not applicable
- Tracking Notes
- Safety and effectiveness in pediatric patients have not been established.
- Body Weight
- 8-10 kg
- Dose
- Not recommended
- Frequency
- Not applicable
- Tracking Notes
- Safety and effectiveness in pediatric patients have not been established.
- Body Weight
- 11-15 kg
- Dose
- Not recommended
- Frequency
- Not applicable
- Tracking Notes
- Safety and effectiveness in pediatric patients have not been established.
- Body Weight
- 16-20 kg
- Dose
- Not recommended
- Frequency
- Not applicable
- Tracking Notes
- Safety and effectiveness in pediatric patients have not been established.
| Body Weight | Dose | Frequency | Tracking Notes |
|---|---|---|---|
| Below 5 kg | Not recommended | Not applicable | Safety and effectiveness in pediatric patients have not been established. |
| 5-7 kg | Not recommended | Not applicable | Safety and effectiveness in pediatric patients have not been established. |
| 8-10 kg | Not recommended | Not applicable | Safety and effectiveness in pediatric patients have not been established. |
| 11-15 kg | Not recommended | Not applicable | Safety and effectiveness in pediatric patients have not been established. |
| 16-20 kg | Not recommended | Not applicable | Safety and effectiveness in pediatric patients have not been established. |
Formulation
Purpose
Galvus is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
Generic Name
VildagliptinScheduled Drug
Yes. This medicine should be supplied or used only according to applicable prescription and regulatory requirements.